Mesenchymal stem cells (hMSCs) have been shown to differentiate into osteoblasts that, in turn, are capable of forming tissues analogous to bone. The present study was designed to investigate the inhibition of osteogenesis by hMSCs. Bone marrow-derived hMSCs were treated with transforming growth factor b-3 (TGFb3) at various doses during or after their differentiation into osteogenic cells. TGFb3 was encapsulated in poly(DL-lactic-co-glycolic acid) (PLGA) microspheres and released via controlled delivery in the osteogenic culture of hMSCs and hMSC-derived osteoblasts for up to 28 days. Controlled release of TGFb3 inhibited the osteogenic differentiation of hMSCs, as evidenced by significantly reduced alkaline phosphatase activity and staining, as well as decreased mineral deposition. After hMSCs had been differentiated into osteoblasts, controlled release of TGFb3 further inhibited not only alkaline phosphatase and mineral deposition but also osteocalcin expression. These findings demonstrate the potential for sustained modulation of the behavior of stem cells and/or stem cell-derived lineage-specific cells via controlled release of growth factor(s). The attenuation of osteogenic differentiation of MSCs may facilitate understanding not only the regulation and patterning of osteogenesis in development but also several pathological models such as osteopetrosis, craniosynostosis, and heart valve calcification.
ABSTRACT
Mesenchymal stem cells (hMSCs) have been shown to differentiate into osteoblasts that, in turn, are capable of forming tissues analogous to bone. The present study was designed to investigate the inhibition of osteogenesis by hMSCs. Bone marrow-derived hMSCs were treated with transforming growth factor b-3 (TGFb3) at various doses during or after their differentiation into osteogenic cells. TGFb3 was encapsulated in poly(DL-lactic-co-glycolic acid) (PLGA) microspheres and released via controlled delivery in the osteogenic culture of hMSCs and hMSC-derived osteoblasts for up to 28 days. Controlled release of TGFb3 inhibited the osteogenic differentiation of hMSCs, as evidenced by significantly reduced alkaline phosphatase activity and staining, as well as decreased mineral deposition. After hMSCs had been differentiated into osteoblasts, controlled release of TGFb3 further inhibited not only alkaline phosphatase and mineral deposition but also osteocalcin expression. These findings demonstrate the potential for sustained modulation of the behavior of stem cells and/or stem cell-derived lineage-specific cells via controlled release of growth factor(s). The attenuation of osteogenic differentiation of MSCs may facilitate understanding not only the regulation and patterning of osteogenesis in development but also several pathological models such as osteopetrosis, craniosynostosis, and heart valve calcification.
Mesenchymal stem cells (MSCs) were first isolated in the 1970s and named fibroblast colony-forming units. [1] [2] [3] The bone marrow is known to be a rich source for heterogeneous cell populations including hematopoietic stem cells and MSCs. 4, 5 Recently, a great deal of effort has been focused on the application of MSCs for therapeutic models such as skeletal, cardiac, and neuronal disorders. MSCs in the adult can be readily extracted by bone marrow aspiration and expanded over more than 20 cumulative population doublings without losing some of their capacity to differentiate into osteoblasts, adipocytes, and chondrocytes. [6] [7] [8] [9] Recently, embryonic stem cells have also been shown to differentiate into osteoblast-like and chondrocyte-like cells. 8, [10] [11] [12] Osteogenic differentiation of MSCs is one of the most studied differentiation pathways. 9, 13, 14 In critical size defects resulting from trauma, congenital anomalies, and tumor resection, bone healing is incomplete without a sufficient number of bone-forming cells. Osteoblasts differentiated from MSCs are potentially critical during bone healing and have been seeded or encapsulated in polymeric scaffolds in 3D for bone tissue engineering. [15] [16] [17] [18] In many instances, mineralized tissue or even bone-like tissues have been formed. [19] [20] [21] MSC differentiation into osteoblasts is known to be regulated by an array of molecular cues. For example, osteoblastic differentiation of hMSCs is stimulated by epidermal growth factor. 9 Replacement of insulin and triiodothyronine with bone morphogenetic protein-4 (BMP-4)-conditioned medium results in the suppression of adipogenesis and increased osteogenic development of embryonic stem cells. 22 Canonical wingless (Wnt) signaling has been increasingly demonstrated to be a critical regulatory pathway of osteogenic differentiation. 23 Inhibition of Wnt signaling may prevent osteogenesis and predispose hMSCs to enter the cell cycle.
14 In addition, osteogenesis is stimulated by BMP-2 and further sustained by Wnt signaling. Down-regulation of Wnt signaling in maturing osteoblasts is necessary for the formation of a mineralized bone matrix. 24, 25 Osteoblastic differentiation controlled by Wnt signaling or transforming growth factor (TGF)b signaling is regulated by the activation of Runx2 gene expression in mesenchymal cells. 26 Deletion of the two Runx2 isoforms, Runx2-II and Runx2-I, results in complete cessation of bone development. 27 Previous effort has overwhelmingly focused on the forward differentiation of somatic or embryonic stem cells toward the osteoblastic lineage. Little is known about the reverse process of osteogenesis, i.e., inhibition of osteogenic differentiation of stem cells. In addition to the potential revelation of regulatory cues in the differentiation mechanisms, several clinical models clearly demand our improved understanding of the inhibition of osteogenic [28] [29] [30] [31] [32] Accelerated osteogenic differentiation in cranial sutures is proposed to be one of the potential causes for craniosynostosis. 31, 33 Ossification of heart valves is a common cause of their degeneration and failure, attributable to the mineralization of interstitial cells and matrices. 34 Understanding the inhibition of osteogenic differentiation may help reveal the mechanisms of heart valve ossification. Undesirable ectopic bone formation also occurs in engineered rabbit tendons from MSCs, and needs to be rectified. 35 In short, there are substantial needs to improve our understanding of the inhibition of osteoblastic differentiation from stem cells, for the understanding of bone development, as well as for devising potential therapeutic approaches for several pathological models as described above. The present study was designed to determine whether osteogenesis from not only MSCs but also MSC-derived osteoblasts can be inhibited by longterm controlled release of TGFb3 from biodegradable microspheres.
MATERIALS AND METHODS
In vitro osteogenic differentiation of hMSCs hMSCs were isolated from donated human bone marrow samples (AllCells, Berkeley, CA) and plated in monolayers in six-well plates at a density of 3Â10 4 cells/well per our previous methods 36 ( Figure 1A and B). The isolated hMSCs were cultured-expanded at 37 1C, 95% humidity, and 5% CO 2 , using Dulbecco's Modified Eagle's Medium (DMEM-c; Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS; Atlanta Biologicals, Norcross, GA), and 1% antibiotic and antimycotic (10,000 U/ mL penicillin [base], 10,000 mg/mL streptomycin [base], 25 mg/mL amphotericin B) (Atlanta Biologicals). 5, 36 Following expansion, hMSC culture was supplemented with osteogenic stimulants (OS) including 100 nM dexamethasone, 0.05 mM ascorbic acid-2-phosphate, and 10 mM bglycerophosphate, per our previous work. 36, 37 Microsphere preparation and TGFb3 encapsulation Microspheres of poly(DL-lactic-co-glycolic acid) (PLGA; Sigma) of 50 : 50 copolymer ratio encapsulating recombinant human TGFb3 (R&D Systems, Minneapolis, MN) were prepared using the double-emulsion technique ([water-in-oil]-in-water) (Figure 2A -C) as per our previously reported technique. 36 Briefly, PLGA (250 mg) was dissolved into 1 mL dichloromethane. A total of 0.5 or 2.5 mg TGFb3 was diluted in 50 mL of 1% Bovine serum albumin phosphate-buffered saline (PBS) solution and added to the PLGA solution, forming a mixture (primary emulsion) that was emulsified for 1 minute (water-in-oil). The primary emulsion was added to 2 mL of 1% polyvinyl alcohol solution (PVA, MW 30,000-70,000) and mixed for 1 minute ([water-in-oil]-in-water). One hundred milliliters of 0.1% PVA solution was added to the mixture and stirred for 1 minute using an electric stirrer at 450 r.p.m. Lastly, 100 mL of 2% isopropanol was added to the final emulsion and continuously stirred for 2 hours under a chemical hood to remove the solvent (450 r.p.m.). The 0.5 mg TGFb3 was considered as the low loading dose, while 2.5 mg TGFb3 the high loading dose. A control group of ''empty'' microspheres was fabricated using the same PLGA microsphere fabrication procedures but encapsulated distilled water, instead of TGFb3. PLGA microspheres encapsulating TGFb3 or distilled water were isolated using filtration (2 mm filter) and washed three times with distilled water. Microspheres were frozen in liquid nitrogen for 30 minutes and freeze-dried for 48 hours. and hMSC-derived osteoblasts (hMSC-Ob-Experiment 2) cultured with osteogenic-supplemented medium (OS) to promote osteogenesis. hMSCs in Experiment 1 were cultured under osteogenic conditions plus transforming growth factor b-3 (TGFb3)-loaded PLGA microspheres or empty microspheres (control) for 4 weeks in vitro. In Experiment 2, a different group of hMSCs was allowed to differentiate into osteoblast-like cells by pre-treatment (OS PT) with OS for ten days with no microspheres (hMSC-Ob). hMSCOb were then cultured in OS for another 3 weeks in the presence of TGFb3 or empty PLGA microspheres. (B) Poly(DL-lacticco-glycolic acid) (PLGA) microspheres are placed on a porous membrane of a transwell insert, which is subsequently placed in the well of a six-well cell culture plate, where hMSC or hMSC-Ob are plated in monolayers, allowing released TGFb3 to diffuse through the porous membrane and come in contact with the underlying cells. Tabulated doses of released TGFb3 from PLGA microspheres refer to the amount of TGFb3 released after 1 week. Cumulative release from the present PLGA microspheres is non-linear and decreases in subsequent weeks.
Lyophilized microspheres were sterilized using ethylene oxide gas. Our previous experience with this fabrication method demonstrated that the average diameter of microspheres falls between 20 and 200 mm. 36 We previously demonstrated that that ethylene oxide gas was nondetrimental and preserved the morphology of PLGA microspheres and release kinetics of growth factors encapsulated. 36 The sterilized PLGA microspheres were maintained at À20 1C until use.
Delivery of TGFb3-encapsulated microspheres to hMSCs and hMSC-derived osteoblasts hMSC (Experiment 1) or hMSC-derived osteoblasts (Experiment 2) were incubated with TGFb3-encapsulated PLGA microspheres at concentrations of 0, 0.035, 0.135, and 1.35 ng/mL ( Figure 1A and B) . Doses of released TGFb3 from PLGA microspheres refer to the amount of TGFb3 released after a 1 week exposure of microspheres to an aqueous environment. Both Experiment 1 and Experiment 2 included OS as described above throughout all time points. The main difference between the two cell types in Experiments 1 and 2 is that in the latter, hMSCs were pretreated with osteogenic supplements for 10 days (hMSC-Ob) before introduction of controlled delivery of TGFb3 from PLGA microspheres or empty microspheres (control). Osteogenic-supplemented medium was changed every 3-4 days. Sterilized PLGA microspheres were added to hMSC or hMSC-Ob cultures using 0.4 mm pore size transwell inserts ( Figure 1B ) (Becton Dickinson Labware, Franklin Lakes, NJ). 38 The transwell inserts allowed the released growth factor to act on the underlying cells without direct contact with microspheres. 36, 38 Released TGFb3 was allowed to diffuse through the transwell insert pores via medium solution and interact with the underlying cell monolayer ( Figure 1B) . Referencing the release kinetics of TGFb3 from PLGA microspheres ( Figure 2D ), values for the amount of TGFb3 released over the first 7 days were used to form four experimental groups: control (empty microspheres), 3 mg of low-concentration microspheres (0.035 ng TGFb3/mL released during first week), 3 mg of high-concentration microspheres (0.135 ng TGFb3/mL released during first week), and 30 mg of high-concentration microspheres (1.35 ng TGFb3/mL released during first week) ( Figure 1B) . The cumulative release of molecules from PLGA microspheres is nonlinear and typically attenuated after the first week; however, sustained exposure to control-released TGFb3 continues throughout the experiment at doses established in release profile studies ( Figure 2D ).
Analysis of inhibitory effects during osteogenesis of hMSCs and hMSC derived osteoblasts
At 7, 14, 21, and 28 days, cell culture samples were collected by the addition of detergent Triton-X 100 (Sigma) to the cell culture for 15 minutes, after the medium had been removed and the cells washed twice with PBS. Using cell scrapers, samples were physically detached and pipetted into a glass test tube. Samples were then lysed by sonication for 20 seconds on ice, and frozen at À70 1C until samples at all time points were collected, and then thawed and assayed. In order to evaluate the potential of TGFb3 in reducing the osteogenic behavior of hMSC-Ob, the above methods were performed not only using (undifferentiated) hMSCs but also hMSC that were pretreated with osteogenic supplements for 10 days ( Figure 1A ) and presented high levels of osteogenic differentiation markers before the addition of TGFb3-loaded PLGA microspheres. Only the highest dose of TGFb3 (1.35 ng/mL released during first week) was used for hMSC-derived osteoblasts in experiment 2. Pretreated hMSC-Ob were cultured with OS for 21 days post pretreatment to complete the experimental timeline ( Figure 1 ). All assays were evaluated using thawed-lysed samples. DNA content was determined using the fluorescent DNA quantification kit (BioRad Labs, Hercules, CA) and expressed in mg DNA per mL of sample. Alkaline phosphatase (ALP) activity was quantified using ALP reagent (RaiChem, San Diego, CA) and expressed as mU/mL, normalized to DNA concentration. ALP staining and Von Kossa staining were used to assess ALP activity and mineral deposition qualitatively. 5, 37 Cell culture wells were fixed with 5% formaline and stained in situ. Osteocalcin was measured using an osteocalcin enzyme linked immunosorbent assay (ELISA) kit (Metra, San Diego, CA).
Statistical analysis
Paired t-tests were used to compare the quantitative alkaline phosphatase activity and osteocalcin levels of hMSCs and hMSC-Ob between the control group (no TGFb3) and each experimental group (TGFb3 released from PLGA microspheres). All statistical analyses were performed with an a level of 0.05 using Minitab 14 software (State College, PA).
RESULTS

PLGA microsphere-encapsulated TGFb3
TGFb3 was encapsulated by PLGA microspheres fabricated using the double-emulsion-solvent-extraction technique (Figure 2A and B) . The topology of the PLGA microspheres encapsulating TGFb3 showed smooth spherical surfaces by scanning electron microscope (SEM) imaging ( Figure 2B ). SEM imaging of a cross-section of microspheres allowed visualization of the crystal-like structure of encapsulated molecules (encapsulation of bovine serum albumin, in Figure 2C ). The average diameter of TGFb3-encapsulating PLGA microspheres was 102 AE 45 mm (Figure 2A and B) . Total encapsulation of TGFb3 in PLGA microspheres resulted in 0.2 and 0.75 ng TGFb3/mL/mg of microspheres for the low and high initial loading concentrations, respectively (low: 0.5 mg TGFb3; high: 2.5 mg TGFb3), as quantified by ELISA. TGFb3 was released up to 35 days/ELISA ( Figure 2D ).
Inhibition of osteogenic differentiation of hMSC
Bone marrow-derived hMSCs in monolayer culture with osteogenic supplements showed a large increase in ALP activity up to 21 days (open bars in Figure 3 ) (p < 0.01). The ALP activity of hMSCs exposed to TGFb3 released from PLGA microspheres at various doses was significantly inhibited by 14 and 21 days (shaded bars in Figure 3 ) (p < 0.01). This is further exemplified by combined ALP and von Kossa staining of TGFb3 incubated hMSCs in culture at 14, 21, and 28 days ( Figure 4B , D, and F), in comparison with gradually increasing ALP staining of control hMSCs without TGFb3 treatment ( Figure 4A , C, and E). ALP was not measured at the late time point of 28 weeks, given its typical effective expression during early osteogenesis (3-21 days). Increasing mineral deposition was detected by von Kossa staining in the control group up to 28 days (no TGFb3) ( Figure 5A-C) , whereas the high TGFb3 dose group (1.35 ng/mL) effectively inhibited mineralization at days 14, 21, and 28 ( Figure 5A-C) . Experimental cell culture wells stained for ALP and mineral deposition (von Kossa) included negative control (hMSCs cultured in DMEM-c), as well as osteogenic cultures with 0, 0.035, 0.135, or 1.35 ng/mL, of TGFb3 up to 28 days ( Figure 5A-C) . Although the inhibition of mineral deposition also occurred in response to lower TGFb3 doses, the high dose was more effective. Since much higher doses of TGFb3 (> 10 ng/mL) are known to induce chondrogenic differentiation of MSCs, 5 we checked chondrogenesis by safranin-O staining for sulfated glycosaminoglycans that are typically found in cartilage. No chondrogenic differentiation was observed in any of the present experimental groups (data not shown).
Inhibition of osteogenesis of hMSC-derived osteoblasts
hMSCs are known to begin differentiating into osteoblasts within 1-14 days of in vitro treatment in osteogenic medium (100 nM dexamethasone, 0.05 mM ascorbic acid-2-phophate, and 100 mM b-glycerophosphate), as per our previous work. 15, 36 In the present study, we differentiated hMSCs into osteoblast-like cells in vitro for 10 days, per our previous approach. These hMSC-Ob showed substantial activity inhibition upon delivery of TGFb3 in PLGA microspheres for up to 28 days in culture, as evidenced by a significant reduction in mineralization ( Figure 6B and D and right plate in Figure 6E ), in comparison with the corresponding controls ( no TGFb3) ( Figure 6A and C and left plate in Figure 6E) . Quantitatively, the controlled release of TGFb3 from 30 mg of high-concentration microspheres (1.35 ng/mL released during the first week) significantly reduced the ALP activity at days 14, 21, and 28 ( Figure 7A) , as well as osteocalcin activity by day 28 ( Figure 7B ) (p < 0.05).
DISCUSSION
Osteogenic differentiation from progenitor cells indicates a commitment to lineage specification and is the first step in osteogenesis. The present data represent an original demonstration of the inhibition of osteogenic differentiation of hMSCs and matrix synthesis of hMSC-derived osteoblasts by the controlled release of TGFb3 for up to 21-28 days. The advantage of controlled release of TGFb3, as opposed to addition in culture medium, is that controlled release enables continuous exposure of cells to the growth factor, and has the potential to avoid rapid denaturation and, if in an in vivo model, rapid diffusion. In order to inhibit osteogenesis, both osteogenic differentiation of progenitor cells and mineral deposition should be attenuated. The present data demonstrate that osteogenic differentiation from stem cells and mineral depposition were both inhibited. TGFb3 is one of the three mammalian isoforms of the TGFb superfamily, and a key regulator of skeletogenesis during development and tissue regeneration. [39] [40] [41] [42] TGFb1 and TGFb2 appear to stimulate osteogenesis and are required for osteoblastic differentiation. 43, 44 In contrast, the actions of TGFb3 on osteogenic differentiation and mineral deposition are yet to be fully understood. The present findings suggest that TGFb3 has dose [45] [46] [47] Moreover, the delivery of exogenous TGFb3 in collagen sponges to cranial sutures results in a decrease in the proliferation of osteoblasts. 48 On the other hand, TGFb2 delivery increases the proliferation of sutural osteoblasts and results in premature sutural ossification. [45] [46] [47] [48] Thus, TGFb2 and TGFb3 seem to mediate different processes of osteogenesis in a reciprocal fashion in cranial sutures. Additional studies utilizing the present approaches are warranted to incorporate other TGFb isoforms for exploring the interplay between TGFb3 and other cytokines. Investigations of cellular activation and regulation by these growth factors, including receptor activity, intracellular signaling pathways, and protein synthesis may elucidate novel regulatory strategies for osteogenesis. Another implication of the present approach involves the regulation of stem cell fate. For instance, embryonic stem cells implanted in mice and rats may form teratomas, indicating that differentiation of progenitors must be controlled postimplantation. 49, 50 Undesired ectopic bone formation occurs in approximately 28% of tissue-engineered rabbit tendon repairs using MSCs. 35 Heterotopic ossification in ligaments, tendons, and muscles such as in fibrodysplasia ossificans progressiva patients leads to stiffness in the affected areas and may also limit movement in affected joints (e.g., knees, wrists, shoulders, spine, and/or neck). [51] [52] [53] [54] Thus, the use of stem cells in skeletal tissue engineering demands their controlled differentiation postimplantation. The present data demonstrate a system that may be used in regulating stem cells during osteogenesis by maintaining their undifferentiated state, and preventing ectopic bone formation in soft-tissue engineering.
Many parameters of microsphere fabrication and delivery to cell culture may be tailored for more accurate and encompassing clinical applications. The present fabrication of PLGA microspheres only included a single PLA : PGA ratio. Variations in the polymer composition and structure may alter the proposed TGFb3 release profile, as shown in our previous work. 36 Different release profiles can be advantageous in the modulation of differentiation behavior of stem cells and/or stem-cell derived lineage-specific cells. Functionalization of PLGA microspheres with agents such as heparin or incorporation into hydrogels may diminish the initial burst effect and linearize the TGFb3 release profile. [55] [56] [57] The fabrication of more similar-sized microspheres may be a potential procedure to decrease the variation of released TGFb3 concentrations. Additionally, the inhibitory effects presented here on the osteogenesis of hMSCs and hMSC-Ob may not be reciprocally correlated, given that the culture time of each experiment was offset by the pre-treatment time of 10 days necessary to initiate osteogenic differentiation of hMSCs in Experiment 2. hMSCs in Experiment 1 were tested for 28 days in osteogenic culture and continuous delivery of TGFb3, whereas hMSCs in Experiment 2 were initially differentiated into hMSC-Ob for 10 days, and then introduced to TGFb3 delivery for another 21 days (total of 31 experimental days). Thus, small timely discrepancies must be considered. Nonetheless, the present approach takes advantage of the versatile and widespread applications of controlled delivery of bioactive molecules from degradable polymer microspheres, in particular the regulation of stem cell fate during osteogenesis and the inhibition of bone matrix formation of differentiated osteoblasts. The inhibition of osteogenic differentiation from progenitor cells may have implications in bone development. For locally resident MSCs, regional TGFb3 concentration likely regulates their differentiation pathways. This speculation can be tested by improving our understanding of potential pathways of TGFb3 actions in the regulation of osteogenesis, and likely parallel pathways such as adipogenesis and angiogenesis. [58] [59] [60] Whether TGFb3 regulates stem cell fate and osteogenesis by regulating intracellular SMAD pathways or by the interactions with other cytokines at the cell surface level warrants additional studies. In wound healing, TGFb3 attenuates the synthesis of collagen type I and furthermore inhibits scar tissue formation. 61, 62 Attenuation of type I collagen synthesis may also be one of the pathways of inhibition of osteogenesis. Such demonstrations elicit many implications in inhibiting keloid formation, skin tissue engineering, and cardiovascular procedures, where fibrous tissue formation and stem cell fate must be regulated.
TGFb3 is a potent chondrogenic factor during MSC differentiation and is highly expressed in the proliferating zone of cartilaginous growth plates. 63 Given its involvement during native chondrogenesis, TGFb3 has been implemented in 2D and 3D in vitro chondrogenic differentiation-engineered models for MSCs. 5, 15, 64 The presently demonstrated controlled delivery of TGFb3 using PLGA microspheres provides tools for continued chondrogenic differentiation of MSCs using a single application of TGFb3-loaded microspheres. Although the concentration of TGFb3 in the present study for the inhibition of MSC osteogenic differentiation and osteoblast matrix synthesis (up to $ 1 ng/mL) is several orders of magnitude lower than required chondrogenic doses ( > 10 ng/mL), the same protocol for microsphere fabrication and encapsulation may be replicated to deliver increased amounts of TGFb3. Increasing the amount of microspheres or the initial TGFb3 loading concentration, as well as biomaterial parameter variations, may result in desirable sustained delivery of chondrogenic doses of TGFb3, illustrating the versatility of this approach in tissue engineering and wound-healing models.
